MSACL 2025 Industry Workshop Presentation *This Podium Presentation is occuring in the context of an Industry Workshop that starts at the time below. Its actual start time may be up to 40 minutes later, depending on order of presentation if there are multiple presentations planned by the workshop host. Workshop Host: Agilent Technologies Day: Wednesday September 24 Time: 7:30* Location: Montreal 6-8 (Track 5)

Serum M-protein analysis for multiple myeloma investigations using the Agilent AssayMap Bravo liquid handler and 6545xt LCQTOF
	Matthew Nichols, MSc, PhD, FCACB Western University and London Health Sciences Centre
Presenter Bio: Matthew Nichols is a board-certified clinical biochemist working at Victoria Hospital, London Health Sciences Centre in London, Ontario, Canada.  At LHSC he oversees toxicology, therapeutic drug monitoring and trace elements analysis. In his role he oversees the method development, validation and implementation of clinical assays utilizing a variety of mass spec techniques, including LC-MSMS, LC-HRMS, ICP-MSMS and GC-MS. For the last several years one of our main projects has been developing a combined liquid handler and LC-QTOF method for the detection of M-proteins in the serum of patients with multiple myeloma.

Mass spectrometry has been an emerging tool to measure and characterize M-proteins in the serum of individuals with multiple myeloma. Mass spectrometry has demonstrated increased sensitivity and specificity relative to conventional serum protein electrophoresis and immunofixation electrophoresis techniques which constitute core components of the biochemical work up for diagnosis and/or disease monitoring. These advances in mass spectrometry as they apply to multiple myeloma are reflected by the incorporation into the international myeloma working group guidelines in 2021. In this talk we will cover our approach to measuring the intact light chain as a personalized M-protein biomarker in the serum of individuals with multiple myeloma and its validation against 218 immunofixation electrophoresis samples. This will cover sample preparation using the AssayMap Bravo in a 96 well format as well as separation and detection using an Agilent Bioenert 1260 Infinity II quaternary pump coupled to an Agilent 6545xt QTOF. QC set up and performance, including mass accuracy, using Daratumumab spiked negative serum will be presented. Further, we will demonstrate the advantages of utilizing mass spectrometry over conventional immunofixation electrophoresis which include lower limits of detection and the ability to distinguish therapeutic monoclonal antibodies from serum M-proteins by highlighting 2 clinical examples.